Navigation Links
Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
Date:9/17/2013

NEW YORK, September 17, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Gilead Sciences Inc. (NASDAQ: GILD), Abbott Laboratories (NYSE: ABT), Actavis Inc. (NYSE: ACT), and Covidien plc (NYSE: COV). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Boston Scientific Corporation Research Report  

On September 12, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has completed enrollment in the EVOLVE II randomized, controlled clinical trial, a study designed to further assess the safety and effectiveness of the SYNERGY Stent System and support US Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions. Kevin Ballinger, President, Interventional Cardiology, Boston Scientific, added, "Completing enrollment of EVOLVE II in just nine months is just one example of how Boston Scientific and the physician community are advancing cardiology together. The SYNERGY product underscores our ongoing commitment to delivering meaningful innovation to the interventional cardiology community and reinforces our position as a global leader in medical devices." The Company informed that the 1,684 Patients enrolled across 125 sites worldwide in the EVOLVE II trial will be followed for five years. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
2. KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization
3. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
4. New Blood Clot Removal System Successfully Restores Blood Flow
5. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
6. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
7. Ensil Canada Announces First Successful Test and Validation of Vastusys Line of Products in Ontario Laboratories
8. Varian Software Successfully Connected with Siemens Linear Accelerators
9. Marken Successfully Launches Quality Agreement Workshop Series
10. Following the Successful Launch in the United States, the New Simbionix U/S Mentor to be Introduced for the First Time in Europe
11. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... NEW YORK, Oct. 6, 2011 Avista Capital Partners, ... has hired Hakan Bjorklund, the departing Chief Executive Officer ... closely with Avista on the development of Nycomed during ... to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion. ...
... Scios Inc. announced an agreement with the United States Department ... a prescription medication for patients with heart failure. ... guilty plea to a single misdemeanor violation of the Food, ... million fine. Scios acknowledges that NATRECOR® was misbranded ...
Cached Medicine Technology:Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 3
(Date:4/22/2014)... spending, a new RAND study concludes that U.S. policy ... and device makers to develop products that produce more ... their use, a new study suggests the study identifies ... created in the first place. The aim is to ... of health as possible and to ensure that costlier ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
(Date:4/22/2014)... been approved since November 2013 for the prevention and ... an early benefit assessment pursuant to the "Act on ... the German Institute for Quality and Efficiency in Health ... an added benefit over the appropriate comparator therapy. ... turoctocog alfa is not proven. As no relevant study ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
(Date:4/22/2014)... of us have gotten stuck in a check-out line ... Mather, assistant professor of physics and an instructor with ... or queues, has been crucial in trying to understand ... of proteins. , The work, submitted during Mather,s first ... the National Science Foundation in the form of a ...
Breaking Medicine News(10 mins):Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:Two genes linked to inflammatory bowel disease 2Health News:Queuing theory helps physicist understand protein recycling 2
... 15 Theranostics Health (THX) today,announced that ... research,collaboration agreement with Duke University. This relationship ... core technologies: Laser,Capture Microdissection (LCM) and Reverse ... these technologies provides a powerful,mechanism to accurately ...
... Corporation, a,subsidiary of Orthopedic Development Corporation, announced today ... treat chronic facet-oriented back,pain or to supplement other ... of the two facet joints in each spinal ... treat intractable back pain without,precluding other options, has ...
... Health Solutions, Corp.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Mark Thierer,President and COO and Jeff ... Capital Markets 12th Annual Spring Investor Conference at the ... on Thursday, May 29,2008 at 10:30 am Eastern Time., ...
... important as intervention, specialists say , , THURSDAY, May 15 ... such as pacemakers and defibrillators emphasize that they,re just ... very specific statement of the importance of optimized medical ... University of Alabama at Birmingham,s Division of Cardiovascular Disease, ...
... American College of Physicians (ACP) proposed today a ... and use of information about clinical and cost-effectiveness ... The recommendations are featured in an article, Cost-Effectiveness ... Effectiveness Entity, published online today in Annals of ...
... BIRMINGHAM, Ala., May 15 Diagnostic Health Corporation,(DHC), ... the appointment of Robert E. Gontarek as its ... this role, Gontarek will oversee,the operations of DHC,s ... Gontarek joins DHC with nearly 20 years ...
Cached Medicine News:Health News:Theranostics Health Signs Research Collaboration Agreement 2Health News:TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels 2Health News:New Guidelines Issued for Implanted Heart Devices 2Health News:Americans must consider cost and effectiveness when comparing and choosing medical interventions 2Health News:Diagnostic Health Corporation Names Robert E. Gontarek as COO 2
... A stethoscope adapter for users of ... and socket" type - must send ... are required. , ,Westone custom ... via our worldwide network of hearing ...
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
Medicine Products: